Phase II Study of Thalidomide (NSC #66847) in Patients With Sarcomas of Gynecologic Origin
- Determine the impact on survival and the antitumor effects of thalidomide in patients
with sarcomas or carcinosarcoma (mixed mesodermal tumors) of gynecologic origin.
- Determine the safety and side effect profiles of the target dose of this treatment
regimen in this patient population.
- Determine the antiangiogenic and immunologic effects of this treatment regimen in these
OUTLINE: Patients receive oral thalidomide daily. Treatment continues in the absence of
disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study within 18 months.
Primary Purpose: Treatment
Scott Wadler, MD
Weill Medical College of Cornell University
United States: Federal Government
|Cancer Center of Albany Medical Center||Albany, New York 12208|
|Mount Sinai School of Medicine||New York, New York 10029|
|NYU School of Medicine's Kaplan Comprehensive Cancer Center||New York, New York 10016|
|New York Medical College||Valhalla, New York 10595|
|University of Wisconsin Comprehensive Cancer Center||Madison, Wisconsin 53792|
|North Shore University Hospital||Manhasset, New York 11030|
|Albert Einstein Clinical Cancer Center||Bronx, New York 10461|
|New York Weill Cornell Cancer Center at Cornell University||New York, New York 10021|
|St. Luke's-Roosevelt Hospital Center - Roosevelt Division||New York, New York 10019|
|St. Vincent's Comprehensive Cancer Center||New York, New York 10011|